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Abstract
A recent genome-wide association study revealed a variant (rs2431697) in an intergenic region,
between the PTTG1 and microRNA (miR-146a) genes, associated with SLE susceptibility. Here,
we analyzed with a case-control design this variant and other candidate polymorphisms in this
region together with expression analysis in order to clarify to which gene this association is
related. The SNPs rs2431697, rs2910164 and rs2277920 were genotyped by TaqMan assays in
1324 SLE patients and 1453 healthy controls of European ancestry. Genetic association was
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statistically analyzed using Unphased. Gene expression of PTTG1, the miRNAs miR-3142 and
primary and mature form of miR-146a in PBMCs were assessed by quantitative real-time PCR. Of
the three variants analyzed only rs2431697 was genetically associated with SLE in Europeans.
Gene expression analysis revealed that this SNP was not associated with PTTG1 expression
levels, but with the microRNA-146a, where the risk allele correlates with lower expression of the
miRNA. We replicated the genetic association of rs2341697 with SLE in a case-control study in
Europeans and demonstrated that the risk allele of this SNP correlates with a downregulation of
the miRNA 146a, potentially important in SLE etiology.
Introduction
The genome-wide association studies (GWAS) that have been carried out in the last years
have revealed a great number of genetic variants predisposing to different complex
autoimmune diseases, including systemic lupus erythematosus (SLE). SLE is a complex
autoimmune disease characterized by the production of autoantibodies, formation of
deleterious immune complexes and systemic inflammation in multiple organs. Aside from
dysregulation of adaptive immunity, many studies have shown the association of innate
immune responses with SLE pathogenesis, such as the involvement of the complement
system, activation of Toll-like and Fcγ receptor-mediated signaling 1. In addition, the
importance of the type I interferon system for disease development was shown 2–4. Many
SLE patients have elevated serum levels of interferon-α (IFN-α), a key regulator of innate
immunity, and increased expression of IFN-α-inducible genes in the white blood cells,
termed the ‘interferon signature’, which could be correlated with both disease activity and
severity, and has also been observed in several other autoimmune diseases 2–4.
In the majority of genetic studies the associations target regions that are far away from
known genes and the biological importance of such variants is rather unknown. In the case
of SLE, a recent GWAS revealed an association signal for a SNP rs2431697 located in an
intergenic region, between the pituitary tumor–transforming 1 (PTTG1) and the
microRNA-146a (miR-146a) genes 5. PTTG1 gene codes for a protein called securin,
primarily important in the regulation of sister chromatid separation during cell division, and
that has been consistently related to several types of cancer 6. miR-146a, on the other hand,
is a microRNA (miRNA) recently described as an important player in the regulation of
innate and adaptive immune system as well as in regulating tumor progression 7.
miRNAs represent a recently discovered class of small, noncoding RNAs, present in
virtually all species. miRNAs have revealed a new mechanism of gene expression
regulation, playing a crucial role in ‘fine-tuning’ negative regulation in many physiological
and pathophysiological processes 8–11. A growing number of miRNAs like miR-125b,
miR-150, miR-155, miR-181a/b, miR-223, miR-101, miR-16 and miR-146a have been
associated with regulation of diverse immune functions including T-cell selection, B cell
maturation and selection, and development of regulatory T cells (Tregs), suggesting that the
microRNA regulatory mechanism may be central in immunological tolerance (reviewed
in 11, 12).
miR-146a was first described in 2006 by Taganov et al 13 in human acute monocytic
leukemia cell line, showing also its upregulation in response to stimulation with
lipopolysaccharides and its role as a negative feedback regulator of the TLR signaling by
targeting tumor necrosis factor receptor-associated factor 6 (TRAF6) and interleukin-1
receptor-associated kinase 1 (IRAK-1), suggesting for the first time its important role as a
negative regulator of inflammation.
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To date, neither the functional role of the SNP rs2431697 nor the gene to which this
association could be related to has been investigated. In this study, we replicated a strong
genetic association of this variant with susceptibility to SLE in Europeans and demonstrated
a correlation of the risk allele of this SNP with lower expression of the miR-146a, relevant
in SLE pathology.
Results
Association of the intergenic variant rs2431697 with SLE
We investigated the genetic association of three candidate SNPs in the PTTG1-miR146a
region (rs2431697, rs2277920 and rs2910164) in a European multicenter collection from 7
European countries. Genotyping call rates were > 95%, and there was no evidence of
deviation from Hardy–Weinberg Equilibrium of any SNP (P > 0.6). By likelihood-based
association analysis (Unphased), there was no association of rs2910164 or rs2277920 (proxy
for rs57095329) with SLE (Table 1). To note, the frequency of the risk allele of rs2277920/
rs57095329 found associated with SLE in Chinese (frequency of 0.16–0.29) was very low in
our European cohort (about 0.027), showing that this risk variant is barely present in
Europeans 14.
rs2910164 is an interesting SNP since it has been shown to affect the efficiency of the
premature miR-146a processing which results in differential expression levels of the mature
miRNA 15. However, no association was found for this SNP with susceptibility to SLE in
our European cohort, which is in concordance to the recent study showing no association of
this variant in Han Chinese either 14.
Our meta-analysis replicated, on the other hand, a robust association of rs2431697 with SLE
(P = 0.00028, OR = 1.23 (1.10–1.38)) with the homozygosity for the risk allele having an
OR of 1.49.
The linkage disequilibrium between those three polymorphisms was proven to be extremely
low (Figure 1 and 2), and thus these variants can be considered as completely independent
markers in this region. Also, considering the whole PTTG1-miR146a region in HapMap,
rs2431697 was found to be rather independent of any major LD block in this region (Figure
1).
Association of rs2431697 with miR146a expression
After confirming the genetic association of rs2431697 with SLE susceptibility in our cohort,
we aimed to analyze if this SNP would have an effect on expression levels on either PTTG1
or miR146a genes. Since this polymorphism is located approximately in the middle between
the two genes (24,23 kb downstream of the PTTG1 gene and 15,3 kb upstream of miR-146a
exon 1), it was unclear to which gene the association of this SNP was related to. We first
attempted to investigate PTTG1 expression levels in PBMC samples with different
genotypes for rs2431697. PTTG1 expression proved to be very low in these cells; however
no difference was seen between the genotypes (Figure 3a). We next analyzed if the SNP was
associated with the expression levels of the mature form of miR-146a, and we found a
decrease of about 1.6-fold in the individuals homozygotes for the risk allele (P = 0.008)
(Figure 3b). The expression levels of mat-miR-146a are known to be dependent on the SNP
rs2910164, which we could corroborate (Figure 3c), however since both variants are not in
LD with each other, this effect is rather independent of rs2910164. In order to validate that
rs2431697 exerts an independent of rs2910164 effect, we analyzed the expression of the
full-length primary miR-146a transcript consisting of two exons. We found that there was
indeed a correlation of rs2431697 with a down regulation of primary miR-146a transcript of
about 2.2-fold (P = 0.009) in ‘risk’ homozygotes (Figures 3dand 3e).
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We further analyzed the expression of the miR-146a transcripts in lymphoblastoid cell lines
(LCLs) with different genotypes. In these cells the expression of PTTG1 and mature
miR-146a was not significantly different between the rs2431697 genotypes (P = 0.663 and P
= 0.057, respectively), although a trend of miR-146a towards decreased levels was seen in
the cells homozygous for the risk allele (Figure 3f). However, when investigating the
primary transcript we could detect a significant difference in expression between genotypes
(P = 0.047) (Figure 3g).
In the latest version of the human genome assembly (hg19) available, a new microRNA
(miR-3142) was annotated in the intronic region of the miR-146a gene (Figure 2). This
microRNA was identified by deep sequencing in a pigment cell and melanoma library 16 and
was included in the miRBase (v.17, April 2011). Since we observed significantly altered
levels of miR-146a primary transcript, we also wondered if it could correlate with miR-3142
levels as well. Thus, we used a TaqMan assay for the mature form of this microRNA in
order to test the expression in both, PBMCs and LCLs. However, we could not detect any
expression of miR-3142 in our samples, although the control snRNA (RNU66) was
expressed at high levels (data not shown).
Discussion
To date, the importance of miRNAs in regulation of many immune processes has been
widely shown and includes examples of regulation of granulopoiesis, T- and B-cell
development and maturation, antigen presentation, Toll-like receptor (TLR) signaling and
cytokine production, immunoglobulin class-switch recombination in B-cells, and T-cell
receptor (TCR) signaling 17. The crucial role of miRNAs in regulating in a ‘fine-tuning’
manner the immune response can be enlighten by the need of the immune system to avoid
uncontrolled and overreacted immune responses, which potentially leads to substantial self-
damage. In fact, the importance of this regulation is demonstrated by the severe impairment
of the development and/or function of immune cells when miRNA expression is
experimentally altered or by the fact that it can be correlated with many different immune-
related diseases 11, 18. Thus, the ablation of miR-146a, the subject of the present study, in
Treg cells in a knockout mouse model led to the development of autoimmune disease with
severe break-down of immunological tolerance, leading to fatal IFN-γ-dependent immune-
mediated lesions in many different organs 7.
Changes in miR-146a expression have been observed in a number of human diseases, such
as inflammatory and autoimmune diseases, viral infections, sepsis, multiorgan failure, and
cancer (reviewed in 19). In the case of autoimmune diseases, numerous studies have shown
that miR-146a is upregulated in synovial tissue and peripheral blood mononuclear cells
(PBMCs) of rheumatoid arthritis (RA) patients 18, 20, 21 as well as in skin lesions of psoriasis
patients 22. On the other hand, miR-146a expression levels were significantly decreased in
PBMCs from patients with Type 2 diabetes 23. The controversial observations on the
expression levels of miR-146a in various autoimmune diseases may be attributed to the
differences in the pathogenic pathways important for different diseases as well as the stage
at which the samples have been taken during disease development.
Tang et al 24 showed a 3-fold downregulation of miR-146a, which negatively correlated
with disease activity and with interferon (IFN) scores in SLE patients. The authors also
reported that beside TRAF6 and IRAK1, miR-146 also regulates the levels of the signal
transducer and activator of transcription 1 (STAT1), and IFN regulatory factor 5 (IRF5), all
of which are key players in the type I IFN pathway. The overexpression of miR-146a in
normal PBMC greatly reduced the induction of type I IFN, while on the other hand the
inhibition of endogenous miR-146a increased its production in response to activation of
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TLR-7. Thus, decreased expression of miR-146a in PBMC may contribute to the enhanced
type I IFN production observed in SLE.
The analysis of serum miR-146a also showed the reduced levels in the serum supernatants
from SLE patients, and that the levels could be correlated with renal function, proteinuria
and disease activity in patients 25.
Polymorphisms affecting miRNA expression, maturation, or mRNA recognition may
represent an important risk determinant in disease susceptibility. In miR-146a, a variant was
described in the passenger strand of the pre-miRNA (rs2910164) that was associated with
susceptibility to papillary thyroid cancer and shown to affect miR-146a processing. This led
to reduced levels of pre-miR-146a as well as mat-miR-146a and eventually to an increased
expression of the target genes, including TRAF6 and IRAK1 15. This SNP has been further
controversially associated with some forms of cancer, such as cervical cancer 26, but failed
to correlate with others 27–29 as well as atrial fibrillation [26]. Interestingly, it was not
associated with psoriatic arthritis 30, neither with RA or SLE in Asians 31, 32, but to our
knowledge this is the first study to investigate the role of this variant in SLE susceptibility in
Europeans. As in the other related diseases, this variant, despite its interesting functional
consequences, is apparently not relevant to SLE susceptibility.
A very recent study also described a variant, rs57095329, in the promoter region of
miR-146a primary transcript associated with SLE in Chinese and with downregulation of
miR-146a expression through reduced binding affinity of the transcription factor Ets-1 14.
According to HapMap data, the frequency of the risk allele identified in this study is very
low in the European (CEU) population (0.017) while in Asian and Africans this variant is
considerably more frequent (0.20–0.24). In our study, we included a SNP rs2277920 located
257 bp downstream of exon 1 donor splice site of the miR-146a primary transcript that could
be of significance to splicing of the full-length transcript. This variant is in complete LD
with rs57095329 found associated with SLE in Chinese and is therefore a proxy of this
polymorphism. We determined that rs2277920 is not significant in conferring susceptibility
to SLE in Europeans and by that also highlight the ethnical difference in the genetic
background of SLE susceptibility and the importance of genetic studies in distinct
populations.
The upstream SNP rs2431697, on the other hand, was first identified as a susceptibility
variant for SLE in a GWAS in Europeans 5 and has later also been genetically associated
with psoriasis in a Chinese GWAS 33, but not with RA in an European case-control study 34.
Considering the opposite expression levels of miR-146a found in SLE and RA
patients 19, 24, it seems coherent the fact that this SNP may not be genetically associated
with RA. The same study that identified the functional SNP rs57095329 also detected a
strong genetic association of rs2431697 as an independent associated locus 14, suggesting
that this variant is most likely a common risk variant among distinct populations.
The molecular mechanism of how the T allele of rs2431697 leads to the downregulation of
miR-146a requires a more detailed analysis. A bioinformatic examination of the region with
rs2431697 was carried out in an attempt to elucidate its potential regulatory role on
miR-146a expression. The SNP is located in the region with high regulatory potential – it
overlaps with the DNase I hypersensitivity cluster and H3K4me3 trimethylation marks as
well as ChIP-seq signals for Pol II and transcription factors NF-kB and PAX5 (Encode
transcription factor ChIP-seq and Encode digital DNaseI hypersensitivity clusters databases,
available at UCSC genome browser (www.http://genome.ucsc.edu/cgi-bin/hgGateway).
Thus, either this variant itself or some others in LD with it may play a role in the regulation
of miR-146a transcription. Further analysis by targeted re-sequencing or fine mapping of
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this region in European SLE patients and controls may possibly reveal the genetic
architecture of the locus and help identify causative variant. It is important to note, that
contrary to the results presented here, in a study by Luo et al (13) this variant was not found
associated with expression of mir146a, but rather its expression was dependent on the alleles
of rs57095329. Given the extremely low frequency of the minor allele of the latter SNP in
Europeans and lack of LD between rs2431697 and rs57095329, we find it difficult to
explain the differential expression of mir146a in Europeans by rs57095329 only. It might be
that the associated region shared between the Europeans and Asians and represented by the
SNP rs2431697 plays a bigger role in miR-146a transcriptional regulation; and further the
gene expression is modulated by ethnic-specific variants. As we showed here, the regulation
takes place at the level of transcription rather than maturation of microRNA, since it affects
the levels of the full-length primary RNA transcript.
It will be of great interest to further investigate the effect of this variant on expression of
miR-146a in specific cell populations of leukocytes. Cell-type specific regulatory
mechanisms may not only affect the expression of the microRNA but lead to the more
dramatic changes in the pattern of genes regulated by miR-146a.
We also do not exclude the possibility that expression of the recently discovered microRNA
miR-3142 located in intron 1 of the miR-146a gene could be dependent on the SNP
rs2431697 as well. Although, according to our data it is not expressed in peripheral
mononuclear blood cells, it still may be expressed in some other tissues.
In summary, we found that rs2431697 is associated with SLE in Europeans and that the T
allele of this SNP correlates with lower expression of the miR-146a gene which could lead
to enhanced function of the target genes involved in type I interferon pathway important for
SLE.
Material and methods
Study subjects
The study group comprised a total of 1 324 SLE patients and 1 453 ethnicity-matched
healthy controls, including 62 patients and 97 controls from Argentina, 63 patients and 70
controls from Belgium, 391 patients and 190 controls from Germany, 75 patients and 57
controls from Hungary, 357 patients and 382 controls from Italy, 175 patients and 176
controls from Portugal and 201 patients and 481 controls from Sweden. All SLE patients
fulfilled the American College of Rheumatology classification criteria for SLE and all
individuals were tested for European ethnicity by principal component analysis.
SNP selection and genotyping
Three SNPs in the PTTG1-miR146a region, rs2431697, rs2277920 and rs2910164 were
chosen to be genotyped in a large case-control European cohort. The SNP rs2431697 is
situated in the intergenic region between the PTTG1 and miR146a genes and has previously
been associated with SLE in a GWAS study in Europeans 5. The second intronic SNP
rs2277920 is located 257 bp downstream of exon 1 donor splice site of the miR-146a
primary transcript and was chosen for genotyping because of its location in the region with
the potential to affect splicing of exon 1. Given that the SNP rs2277920 is a proxy (r2=1 in
1000 genomes pilots for CEU and CHB+JPT) of rs57095329, the SNP recently found
associated with SLE in Chinese 14, the results obtained for rs2277920 in our European
cohort could be attributed to rs57095329. The third SNP rs2910164 is located in the
miR-146a passenger strand and has been shown to influence the expression levels of the
mature miR-146a 15, but its association with SLE or any other autoimmune diseases in
Europeans had not been investigated yet. All SNPs were genotyped by TaqMan® allelic
Löfgren et al. Page 6
Genes Immun. Author manuscript; available in PMC 2013 May 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
discrimination assays (Applied Biosystems). All genotyping was performed at Uppsala
University using ABI PRISM 7900HT Fast Real-Time PCR System.
Statistical analysis of genetic association
Allelic and genotypic association of the polymorphisms with SLE was evaluated using
Unphased version 3.1.5, including the country of origin as a stratification variable. Pairwise
linkage disequilibrium analysis of the PTTG1-miR-146a region and Hardy-Weinberg
equilibrium tests were performed with Haploview version 4.2.
GraphPad Prism software was used for statistical analysis and calculation of mean ± SEM
values of the gene expression data. Comparisons were performed using two-tailed unpaired
t-test.
Gene expression analysis
For the analysis of expression levels of PTTG1, miR-146a and miR-3142, total RNA was
extracted with TRIzol reagent (Invitrogen) from 87 PBMC samples collected from healthy
Swedish individuals at Uppsala University Hospital. In addition, we analyzed expression of
these genes in fourty-four lymphoblastoid cell lines (LCLs) with different genotypes. cDNA
was synthesized from 2 μg of total RNA at 42°C for 80 min followed by heat inactivation at
95°C for 5 min. The reaction contained 1.25 μM random hexamers, MuLV transcriptase,
RNase inhibitor and buffer supplemented with 5mM MgCl2 and 1mM dNTPs. Quantitative
PCR (qPCR) for PTTG1, the primary transcript of miR-146a (pri-miR-146a) and 18S rRNA
were performed using 15 ng cDNA, PCR buffer, 1.5 mM MgCl2, 200 μM dNTPs, 0.5 U
Platinum Taq polymerase (Invitrogen), 0.25 μM of each primer and SYBR Green
(Molecular Probes) for amplification detection. The PCR conditions were as follows:
denaturation at 95°C for 5 min, followed by 40 cycles of 15 sec at 95°C, 15 sec at 60°C, 30
sec at 72°C and final extension at 72°C for 3 min. Expression of PTTG1 and pri-miR-146a
were normalized by that of 18S rRNA. The primers used were as follows: PTTG1-forward:
GCGGCTGTTAAGACCTGCAATAATCCA, PTTG1-reverse:
GTTCGATGCCCCACCAGCCT pri-miR-146aforward:
TTAGGAGCTCGCTGGCTGGGACA; pri-miR-146areverse:
CAGGATCTACTCTCTCCAGGTCCTCA. Mature microRNAs (miR146a, miR3142) and
the snRNA-control RNU66 were reverse transcribed and quantified with TaqMan®
microRNA expression assays (ABI assay IDs 000468, 244120-mat and 001002,
respectively), according to manufacturer’s instructions. Briefly, cDNA was produced from
10 ng of total RNA with the commercial miRNA-specific stem-loop primers. Quantitative
PCR was performed using the specific microRNA TaqMan assay.
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The Italian collaborative participants are:
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Reumatologia Ospedale San Camillo, Roma – Italy), Enrica Bozzolo, Maria Grazia
Sabbadini (IRCCS San Raffaele Hospital, Milan, Italy), Mauro Galeazzi, (Siena University,
Siena, Italy), Sergio Migliaresi, Giovanni La Montagna (Rheumatology Unit Second
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Figure 1.
Linkage disequilibrium (LD) structure of the SNPs in the PTTG1-miR-146a region
generated from HapMap (release 28) with Haploview v. 4.2. LD blocks (r2) were defined
using the solid spine method.
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Figure 2.
Schematic representation of the PTTG1-miR146a genomic region and the position of the
SNPs analyzed. Exons are shown as black bars and dotted line represents the intergenic
region. The location of the two mature miRNA annotated in this region, miR-3142 and
miR-146a, are indicated in the pri-miR-146a transcript. The positions of the four SNPs
included in this study are indicated, together with the LD plot showing the linkage (r2)
between them (generated with Haploview from our genotyping data, except for the LD
between rs2277920-rs57095329 (*) that was extracted from 1000 genomes pilots for CEU
and CHB+JPT).
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Figure 3.
PTTG1 and miR-146a gene expression analysis in PBMCs (a–e) and LCLs (f and g) from
healthy donors, stratified by genotypes. No association was seen with PTTG1 expression (a)
neither for rs2910164 with the primary transcript of miR-146a (e). As for corroboration of
previous findings, rs2910164 correlated with miR-146a expression levels (c). Both mature
and primary form of miR146a were significantly down-regulated in individuals’
homozygotes for the risk allele of rs2431697 (b and d). miR-146a expression analysis in
LCLs also showed a trend of down-regulation of mat-miR146a (f) and statistically lower
levels of pri-miR-146a (g) in cells from individuals homozygotes for the rs2431697 risk
allele. Values correspond to means ±SEM error bars. Expression levels were normalized to
18S rRNA.
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